Longitude Venture Partners III, L.P.'s Net Worth

$279 Million

Who is Longitude Venture Partners III, L.P.?

Longitude Venture Partners III, L.P. has an estimated net worth of $279 Million. This is based on reported shares across multiple companies, which include Inozyme Pharma, Inc., Axonics Modulation Technologies, Inc., Talaris Therapeutics, Inc., Sierra Oncology, Inc., 89bio, Inc., and Molecular Templates, Inc..

SEC CIK

Longitude Venture Partners III, L.P.'s CIK is 0001674099

Past Insider Trading and Trends

2020 was Longitude Venture Partners III, L.P.'s most active year for acquiring shares with 11 total transactions. Longitude Venture Partners III, L.P.'s most active month to acquire stocks was the month of October. 2020 was Longitude Venture Partners III, L.P.'s most active year for disposing of shares, totalling 7 transactions. Longitude Venture Partners III, L.P.'s most active month to dispose stocks was the month of April. 2020 saw Longitude Venture Partners III, L.P. paying a total of $12,999,975.00 for 4,418,724 shares, this is the most they've acquired in one year. In 2022 Longitude Venture Partners III, L.P. cashed out on 3,616,896 shares for a total of $19,498,050.00, their largest year based on trade value.